Protagonist Therapeutics Inc (PTGX)
24.66
-1.04
(-4.05%)
USD |
NASDAQ |
Apr 25, 16:00
Protagonist Therapeutics Price to Book Value: 4.268 for April 25, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| April 25, 2024 | 4.268 |
| April 24, 2024 | 4.448 |
| April 23, 2024 | 4.647 |
| April 22, 2024 | 4.606 |
| April 19, 2024 | 4.433 |
| April 18, 2024 | 4.365 |
| April 17, 2024 | 4.426 |
| April 16, 2024 | 4.519 |
| April 15, 2024 | 4.601 |
| April 12, 2024 | 4.680 |
| April 11, 2024 | 4.788 |
| April 10, 2024 | 4.826 |
| April 09, 2024 | 5.042 |
| April 08, 2024 | 4.862 |
| April 05, 2024 | 4.846 |
| April 04, 2024 | 4.786 |
| April 03, 2024 | 4.859 |
| April 02, 2024 | 4.845 |
| April 01, 2024 | 4.895 |
| March 28, 2024 | 5.008 |
| March 27, 2024 | 4.930 |
| March 26, 2024 | 4.846 |
| March 25, 2024 | 4.827 |
| March 22, 2024 | 4.852 |
| March 21, 2024 | 4.907 |
| Date | Value |
|---|---|
| March 20, 2024 | 4.999 |
| March 19, 2024 | 4.988 |
| March 18, 2024 | 4.926 |
| March 15, 2024 | 5.016 |
| March 14, 2024 | 4.907 |
| March 13, 2024 | 5.227 |
| March 12, 2024 | 5.170 |
| March 11, 2024 | 5.213 |
| March 08, 2024 | 5.248 |
| March 07, 2024 | 5.347 |
| March 06, 2024 | 5.412 |
| March 05, 2024 | 5.359 |
| March 04, 2024 | 5.478 |
| March 01, 2024 | 5.565 |
| February 29, 2024 | 5.258 |
| February 28, 2024 | 5.267 |
| February 27, 2024 | 5.122 |
| February 26, 2024 | 5.111 |
| February 23, 2024 | 4.930 |
| February 22, 2024 | 4.793 |
| February 21, 2024 | 4.590 |
| February 20, 2024 | 4.667 |
| February 16, 2024 | 4.808 |
| February 15, 2024 | 4.839 |
| February 14, 2024 | 4.779 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
1.138
Minimum
Jun 13 2022
11.04
Maximum
Jun 25 2020
4.011
Average
3.898
Median
Jul 19 2023
Price to Book Value Benchmarks
| SELLAS Life Sciences Group Inc | -- |
| Arvinas Inc | 3.251 |
| Akebia Therapeutics Inc | -- |
| Immuneering Corp | 0.4682 |
| Moderna Inc | 2.925 |
Price to Book Value Related Metrics
| Price | 24.66 |
| Earnings Yield | -6.04% |
| Market Cap | 1.437B |